US2003223960A1PendingUtilityA1

Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

38
Priority: Apr 5, 2001Filed: Apr 15, 2003Published: Dec 4, 2003
Est. expiryApr 5, 2021(expired)· nominal 20-yr term from priority
Inventors:Joseph Wettstein
A61P 25/00A61K 31/277A61K 31/165
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a method of treating multiple sclerosis by the use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide in combination with another compound, which is effective in the treatment of multiple sclerosis.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating multiple sclerosis comprising administering to a patient in need of said treatment an effective amount of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide or a pharmaceutically acceptable salt thereof in combination with an effective amount of a compound known to be effective in the treatment of multiple sclerosis.  
     
     
         2 . The method of  claim 1 , wherein said compound known to be effective in the treatment of multiple sclerosis is selected from the group consisting of interferon beta 1-a, interferon beta 1-b, interferon alpha 2, glatrimer acetate, dexamethasone, methyl prednisone, prednisone, methotrexate, azathioprine, cladribine, cyclophosphamide and cyclosporine.  
     
     
         3 . The method of  claim 2 , wherein said compound is interferon beta 1-a.  
     
     
         4 . The method of  claim 2 , wherein said compound is interferon beta 1-b.  
     
     
         5 . The method of  claim 2 , wherein said compound is interferon alpha 2.  
     
     
         6 . The method of  claim 2 , wherein said compound is glatrimer acetate.  
     
     
         7 . The method of  claim 2 , wherein said compound is dexamethasone.  
     
     
         8 . The method of  claim 2 , wherein said compound is methyl prednisone.  
     
     
         9 . The method of  claim 2 , wherein said compound is prednisone.  
     
     
         10 . The method of  claim 2 , wherein said compound is methotrexate.  
     
     
         11 . The method of  claim 2 , wherein said is azathioprine.  
     
     
         12 . The method of  claim 2 , wherein said compound is cladribine.  
     
     
         13 . The method of  claim 2 , wherein said compound is cyclophosphamide.  
     
     
         14 . The method of  claim 2 , wherein said compound is cyclosporine.  
     
     
         15 . A pharmaceutical composition comprising a combination of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide or a pharmaceutically acceptable salt thereof and a compound known to be effective in the treatment of multiple sclerosis.  
     
     
         16 . The composition of  claim 15 , wherein said compound known to be effective in the treatment of multiple sclerosis is selected from the group consisting of interferon beta 1-a, interferon beta 1-b, interferon alpha 2, glatrimer acetate, dexamethasone, methyl prednisone, prednisone, methotrexate, azathioprine, cladribine, cyclophosphamide and cyclosporine  
     
     
         17 . The composition of  claim 16 , wherein said compound is interferon beta 1-a.  
     
     
         18 . The composition of  claim 16 , wherein said compound is interferon beta 1-b.  
     
     
         19 . The composition of  claim 16 , wherein said compound is interferon alpha 2.  
     
     
         20 . The composition of  claim 16 , wherein said compound is glatrimer acetate.  
     
     
         21 . The composition of  claim 16 , wherein said compound is dexamethasone.  
     
     
         22 . The composition of  claim 16 , wherein said compound is methyl prednisone.  
     
     
         23 . The composition of  claim 16 , wherein said compound is prednisone.  
     
     
         24 . The composition of  claim 16 , wherein said compound is methotrexate.  
     
     
         25 . The composition of  claim 16 , wherein said compound is azathioprine.  
     
     
         26 . The composition of  claim 16 , wherein said compound is cladribine.  
     
     
         27 . The composition of  claim 16 , wherein said compound is cyclophosphamide.  
     
     
         28 . The composition of  claim 16 , wherein said compound is cyclosporine.  
     
     
         29 . The composition of  claim 15  wherein the combination is with or without a pharmaceutically acceptable carrier or adjuvant.  
     
     
         30 . A process for producing a pharmaceutical composition comprising combining (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide or a pharmaceutically acceptable salt thereof and a compound known to be effective in the treatment of multiple sclerosis.  
     
     
         31 . The process of  claim 30 , wherein the pharmaceutical composition prepared is useful for the treatment of multiple sclerosis.  
     
     
         32 . A pharmaceutical composition for the treatment of multiple sclerosis comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide and a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2003223960A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.